Lv11
98 积分 2026-03-17 加入
A Novel Designed Anti-PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity
7小时前
已完结
Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody
1个月前
已完结
Extracellular targeted protein degrader removes antibodies in first test in humans
1个月前
已完结
CD200R signaling in tumor tolerance and inflammation: A tricky balance
1个月前
已完结
2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus
2个月前
已完结
Taming the inflamed heart
2个月前
已完结
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
2个月前
已完结
Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective
3个月前
已完结
Resetting autoimmune disease with CAR cell therapies
3个月前
已完结
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
3个月前
已完结
皖公网安备34019202002308
